Diagnostic Kits/Data, narratives and tools produced by the Kits' sector
NOTE: Also see Commons based cases in Kits
Types of inputs for kits
Genetic Diagnostic Case Studies
The following are summaries of IP and commercialization information of commercially available diagnostic kits. A subset of this list will be developed into more extensive case studies. The old spreadsheet form of this information is available here.
Breast and Ovarian Cancer
SACGHS Pipeline:
- Basic and Clinical Research
- Development
- Commercialization
- Communication/Marketing
- Adoption by Clinical Providers and Testing Laboratories
- Adoption by Third-Party Payers
- Consumer Utilization
Important Points from the SACGHS review:
- Myriad has not enforced its patents against researchers (SACGHS Appendix 1, A-2)
- Myriad has not enforced patents for services it does not provide (SACGHS Appendix 1, A-4)
- Data shows little price effect of the BRCA patents (SACGHS Appendix 1, A-4)
- "It is therefore difficult to attribute reduced access to BRCA testing to patents. We cannot exclude the possibility that patent holder’s investments in education about hereditary breast and ovarian cancer (HBOC) and testing have actually had the opposite effect of increasing access to testing" (SACGHS Appendix 1, A-7)
BRCA1
At a glance:
Gene | BRCA1 |
Patent Holders | Myriad Genetics |
Key Patents | 5753441, 6051379 |
Other Patents | |
Licenses | exclusive |
US Test providers | 1 |
Test | BRACAnalysis ($3120) - includes BRCA1 & BRCA2 |
Test cost | $3120 |
BRCA2
At a glance:
Gene | BRCA2 |
Patent Holders | Myriad Genetics |
Key Patents | 5753441, 6051379 |
Other Patents | |
Licenses | exclusive |
US Test providers | 1 |
Test | BRACAnalysis ($3120) - includes BRCA1 & BRCA2 |
Test cost | $3120 |
colorectal cancer (HNPCC)
MLH1
Used to diagnose colorectal cancer (HNPCC)
snpedia
At a glance:
Gene | MLH1 |
Patent Holders & Licensing | Oregon Health Sciences University + Dana Farber; Johns Hopkins |
US Test providers | Baylor, Boston University, City of Hope, Harvard, Huntington, Mayo Clinic, University of Pennsylvania, Quest, Myriad, (9) |
Key Patents | 5922855, 5591826 (protein), 5693470 |
Other Patents | |
Licenses | ? |
Test | |
Test cost | Myriad, MLH1 + MSH2 + MSH6: $2950; see (ref2 pA-12) for more prices |
- notes
- this is a template entry
MSH2
Used to diagnose...
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
- this is a template entry
MSH6
Used to diagnose...
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
- this is a template entry
colorectal cancer (FAP)
APC
Used to diagnose...
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
- this is a template entry
MYH
Used to diagnose...
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
- this is a template entry
Alzheimer's Disease
Important Points from the SACGHS review: (Keep in mind that in this case study this is Duke writing about some of their own patents)
- "An argument can be made that patents were part of the mix of motivations that spurred innovation in Alzheimer’s research." (SACGHS Appendix 1, B-14)
- "At least in the initial period of discovery, the patenting landscape encouraged research, or at least did not dramatically hinder it." (SACGHS Appendix 1, B-14)
- Athena Diagnostics controls the testing market in this area due to patents. The positive and negative effects of this are not clear. (SACGHS Appendix 1, B-15)
- Palombi presents anecdotal evidence that a patent thicket is forming around Alzheimer's research and preventing commercialization of diagnostics and treatments (Palombi p.25).
APOE
Used to diagnose Late Onset Alzheimer's Disease (LOAD, AD2)
http://snpedia.com/index.php/Alzheimer's_disease
At a glance:
Gene | APOE |
Patent Holders & Licensing | Duke university -> Athena Diagnostics |
US Test providers | Athena Diagnostics* (1) |
Key Patents | 5508167, 5716828, 6027896 |
Other Patents | |
Licenses | exclusive |
Test | ADmark® ApoE Genotype Analysis & Interpretation - Symptomatic |
Test cost | $475 |
- patent details
- 2 method patents for Diagnosing Alzheimer’s that don’t claim sequence; Bilski outcome could destabilize. One patent claims a kit. see ref2 pB-6 for more details.
- effects of patents
- Cook-Deegan notes “penumbra effect” with regard to Athena Diagnosics. Athena sublicensed APOE for Direct-to-consumer (DTC) testing to Smart Genetics, but the first inventor on the patent raised licensing complaints for ethical reasons (ref2 pB-16). APOE also is a marker for cardiovascular disease; testing for which does not infringe the methods patents, see ref2 pB-8. Also 2 testing labs in Canada, McGill and Sunnybrook both offer APOE testing for AD for $100 & $120 respectively ref2 pB-8.
PSEN1
Used to diagnose early-onset Alzheimer's Disease (EOAD, AD3)
snpedia
At a glance:
Gene | PSEN1 |
Patent Holders & Licensing | Hospital for Sick Children, U Toronto -> Athena |
US Test providers | Athena Diagnostics (1) |
Key Patents | 6194153 |
Other Patents | 5986054, 6531586, 6248555 (dropped) |
Licenses | exclusive |
Test | ADmark® PS-1 DNA Sequencing Test |
Test cost | $1675 (ref2 pB-15) |
PSEN2
Used to diagnose early-onset Alzheimer's Disease (EOAD, AD4)
snpedia
At a glance:
Gene | PSEN2 |
Patent Holders & Licensing | Hospital for Sick Children -> Athena |
US Test providers | Athena Diagnostics (1) |
Key Patents | 5840540 |
Other Patents | 5840540 |
Licenses | exclusive |
Test | ADmark® PS-2 DNA Sequencing Test |
Test cost | $1500? |
APP
Used to diagnose early-onset Alzheimer's Disease (EOAD, AD1)
snpedia
At a glance:
Gene | APP |
Patent Holders & Licensing | Hospital for Sick Children -> Athena |
US Test providers | Athena Diagnostics, Signature Genomics (2) |
Key Patents | ? |
Other Patents | |
Licenses | ? |
Test | ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH |
Test cost | $1500? |
- notes
- Signature genomics provides a FISH-based test for APP; only Athena does complete sequencing
Haemochromatosis
HFE
Used to diagnose Haemochromatosis
snpedia
At a glance:
Gene | HFE |
Patent Holders & Licensing | Bio-Rad |
US Test providers | |
Key Patents | ? |
Other Patents | |
Licenses | ? |
Test | mDx Hereditary Hemochromatosis ASR kit; mDx Hereditary Hemochromatosis LLA ASR |
Test cost |
- notes
- Merz JF, Kriss AG, Leonard DGB, Cho MK. Op. cit. Examine licensing activities around HFE and impact on diagnostic prices (Merz, J.F. et al., 2002. Diagnostic testing fails the test. Nature, 415(6872), 577-579.(Garcia & Shimizu 1997) Available at: http://repository.upenn.edu/bioethics_papers/48/ [Accessed August 5, 2009].)
- "Patents exist on the HFE gene, its related protein, genetic screening test methods, and related testing kits." (E-2)
- "HFE patents do not appear to have blocked commercial development of additional methods of HFE testing utilizing different platform technologies."(E-4)
Cystic Fibrosis
CFTR
Used to diagnose Cystic Fibrosis
snpedia
At a glance:
Gene | CFTR |
Patent Holders & Licensing | University of Michigan, Hospital for Sick Children |
US Test providers | Many (112) |
Key Patents | 5776677 |
Other Patents | 5876974, 7118911, 6984487, 6730777, 5407796 |
Licenses | non-exclusive |
Test | ADmark® APP DNA Sequencing/Duplication Test; SignatureFISH |
Test cost | $1500? |
- notes
- Johns Hopkins also has some key CFTR patents.
- The licensing of Cystic Fibrosis IP has been non-exclusive and broad and has resulted in a myriad variety of diagnostics. (or is the demand for CF Dx greater than other diseases?)
Spinocerebellar Ataxia
gene
Used to diagnose Spinocerebellar Ataxia.
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | Athena Diagnostics |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | exclusive |
Test | |
Test cost |
- notes
Tay-Sachs Disease
gene
Used to diagnose Tay-Sachs Disease.
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
gene
Used to diagnose Canavan Disease.
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
Coumadin (Warfarin) sensitivity
CYP2C9
Used to predict sensitivity to Coumadin (Warfarin).
snpedia
At a glance:
Gene | CYP2C9 |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test |
Test cost |
- notes
VKORC1
Used to predict sensitivity to Coumadin (Warfarin).
snpedia
At a glance:
Gene | VKORC1 |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
Sprycel (dasatinib) sensitivity
BCR-ABL
Used to predict sensitivity to Sprycel (dasatinib)
snpedia
At a glance:
Gene | BCR-ABL |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
disease
gene
Used to diagnose...
snpedia
At a glance:
Gene | |
Patent Holders & Licensing | |
US Test providers | |
Key Patents | |
Other Patents | |
Licenses | |
Test | |
Test cost |
- notes
- this is a template entry